| Name | LY2886721 |
| Description | LY2886721, a BACE inhibitor, is used for the therapy of Alzheimer's Disease. |
| Kinase Assay | The CTLs and NK cells (0.8×106/mL) are treated with the inhibitors L1 (10-20 μM) or Aloxistatin (20-30 μM) for 24 hr at 37°C in 24-well plates. Cells are then used in 51Cr-release assays or are lysed to examine perforin in Western blots. The inhibitor is also added at the same concentration during the 4 hr reactions in some 51Cr-release assays, as indicated. Cell lysates are prepared using NP-40 lysis buffer (25 mM HEPES, 250 mM NaCl, 2.5 mM ethylenediaminetetraacetic acid, 0.1% volume/volume Nonidet P-40) and total protein concentration is determined using the Bradford assay. Equal amounts of protein are loaded and resolved on 8% SDS-PAGE gels. Human or mouse perforin is detected using the appropriate antibodies as indicated. Anti-actin antibody is used as a loading control[2]. |
| In vitro | LY2886721 is an oral, small molecule of β-site amyloid protein cleaving enzyme (BACE) inhibitor with the potential to inhibit the synthesis of β-amyloid and thereby to slow the Clinicalal progression of AD. [1] LY2886721 can also targetγ-secretase to nhibit the synthesis of β-amyloid. [2] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | Ethanol : < 1 mg/mL (insoluble or slightly soluble)
H2O : < 1 mg/mL (insoluble or slightly soluble)
DMSO : 1 mg/ml, Sonication is recommended.
|
| Keywords | BACE2 | Inhibitor | BACE | Beta-secretase | BBB | Alzheimer's | BACE1 | sAPPβ | LY 2886721 | LY2886721 | C99 | LY-2886721 | inhibit | disease | β-Secretase |
| Inhibitors Related | Eslicarbazepine Acetate | Auraptene | Verubecestat | DSS30 | LX2343 | Loganin | Atabecestat | Phytic acid potassium | NB-360 | Epiberberine | Tenuifolin | Aloeresin D |
| Related Compound Libraries | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Anti-Alzheimer's Disease Compound Library | Drug Repurposing Compound Library | Inhibitor Library | NO PAINS Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | Fluorochemical Library |
United States
